Senti Biosciences Holdings (SNTI) Total Liabilities (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Total Liabilities of $45.6 million for Q4 2025, down 3.08% year-over-year from $47.1 million in Q4 2024, and up 2.4% quarter-over-quarter from $44.6 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Total Liabilities (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Total Liabilities history runs 5 years deep, the most recent figure standing at $45.6 million for Q4 2025.
- In Q4 2025, Total Liabilities fell 3.08% year-over-year to $45.6 million; the TTM figure through Dec 2025 stood at $45.6 million (down 3.08% YoY), while the FY2025 annual figure was $45.6 million, down 3.08% from the prior year.
- Total Liabilities for Q4 2025 stood at $45.6 million, up from $44.6 million in the prior quarter.
- The five-year high for Total Liabilities was $53.5 million in Q4 2022, with the low at $349835.0 in Q1 2021.
- The 5-year median for Total Liabilities is $45.3 million (2025), against an average of $38.4 million.
- The sharpest annual moves came in 2022 and 2024: Total Liabilities surged 3073.28% in 2022, then retreated 14.55% in 2024.
- Senti Biosciences Holdings' Total Liabilities stood at $36.3 million in 2021, then soared by 47.36% to $53.5 million in 2022, then retreated by 1.79% to $52.6 million in 2023, then slipped by 10.43% to $47.1 million in 2024, then slipped by 3.08% to $45.6 million in 2025.
- Business Quant data shows SNTI's Total Liabilities at $45.6 million in Q4 2025, $44.6 million in Q3 2025, and $43.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Senti Biosciences Holdings | 13.66 Mn | 13.66 Mn | - | 36.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 45.63 Mn |
| Sep 30, 2025 | 44.56 Mn |
| Jun 30, 2025 | 43.89 Mn |
| Mar 31, 2025 | 44.92 Mn |
| Dec 31, 2024 | 47.09 Mn |
| Sep 30, 2024 | 41.73 Mn |
| Jun 30, 2024 | 42.77 Mn |
| Mar 31, 2024 | 46.09 Mn |
| Dec 31, 2023 | 52.57 Mn |
| Sep 30, 2023 | 48.83 Mn |
| Jun 30, 2023 | 46.21 Mn |
| Mar 31, 2023 | 49.09 Mn |
| Dec 31, 2022 | 53.53 Mn |
| Sep 30, 2022 | 49.10 Mn |
| Jun 30, 2022 | 48.10 Mn |
| Mar 31, 2022 | 11.10 Mn |
| Dec 31, 2021 | 36.33 Mn |
| Sep 30, 2021 | 8.18 Mn |
| Jun 30, 2021 | 8.11 Mn |
| Mar 31, 2021 | 349,835.00 |